Versatile performance edges of HBsAg Next assay in diagnosis and therapeutic monitoring of HBV infection.

Autor: Steve RJ; Department of Clinical Virology, Christian Medical College, Vellore, India., Prakash A; Department of Clinical Virology, Christian Medical College, Vellore, India., Ponnuvel S; Department of Clinical Virology, Christian Medical College, Vellore, India., Dickson CJ; Department of Clinical Virology, Christian Medical College, Vellore, India., Nandan K; Department of Clinical Virology, Christian Medical College, Vellore, India., Singh B; Department of Clinical Virology, Christian Medical College, Vellore, India., Sam GA; Department of Transfusion Medicine and Immuno-haematology, Christian Medical College, Vellore, India., Goel A; Department of Hepatology, Christian Medical College, Vellore, India., Zachariah UG; Department of Hepatology, Christian Medical College, Vellore, India., Eapen CE; Department of Hepatology, Christian Medical College, Vellore, India., Kannangai R; Department of Clinical Virology, Christian Medical College, Vellore, India., Abraham P; Department of Clinical Virology, Christian Medical College, Vellore, India., Fletcher GJ; Department of Clinical Virology, Christian Medical College, Vellore, India. Electronic address: fletchergj@cmcvellore.ac.in.
Jazyk: angličtina
Zdroj: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology [J Clin Virol] 2023 Mar; Vol. 160, pp. 105378. Date of Electronic Publication: 2023 Jan 11.
DOI: 10.1016/j.jcv.2023.105378
Abstrakt: Background: HBsAg Next assay (HBsAgNx) claims improved detection of HBsAg. The aim was to investigate its performance in ascertaining HBsAg loss, ability to detect HBsAg in various phases of HBV infection, specificity and its amenability to in-house neutralization.
Methods: Analytical sensitivity was investigated using NIBSC standard (3rd WHO-IS). For clinical performance, out of 91,962 samples tested for HBsAg (Qual-II), 512 samples consisting of 170 cases with evidence of HBsAg loss during treatment (n = 116) and without treatment (n = 54), acute-hepatitis B (n = 90) and acute exacerbation of chronic-hepatitis B (n = 41), acute-hepatitis A (n = 24) and acute-hepatitis E (n = 9) positive, HIV-1 positive (n = 20), non-HBV, HAV and HEV related acute-hepatitis (n = 81) and HBsAg prozone (n = 14) as well as in-house neutralization (n = 63) were included.
Results: The calculated limit of detection (LOD) was 0.004 IU/mL. Of the 170 patients with apparent HBsAg loss, 18/116 (15.5%) among treated and 15/54 (27.7%) with spontaneous clearance were positive in HBsAgNx (p < 0.0001). Additionally, it detected HBsAg in 12/95 (12.6%) and 6/34 (17.6%) patients who were HBV DNA negative in treatment experienced and spontaneous clearance groups respectively (p < 0.001). The specificity of HBsAgNx was comparable to HBsAg Qual-II. The signal-intensity of HBsAgNx was significantly higher than HBsAg Qual-II across various phases of HBV infection and prozone samples.
Conclusion: HBsAgNx significantly enhanced the accuracy of HBsAg detection without compromising the specificity in ascertaining HBsAg loss. The performance was superior in various phases of HBV infection including samples that exhibited prozone effect. Furthermore, it is amenable to cost-effective in-house neutralization to confirm low HBsAg levels.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: